Halozyme Therapeutics | HALO - Fremdkapital

Aktienkurs
62.87
Täglich Wechseln
-0.56 -0.88%
Monatlich
-10.65%
Jährlich
-1.80%
Q1 Prognose
61.53




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Baxter International USD 9.47B 726M 2025-12
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.12B 957.23M 2025-12
DBV Technologies USD 0 0 2025-03
Eli Lilly USD 40.87B 5.6M 2025-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
MannKind USD 548.44M 244.79M 2025-12
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Pfizer USD 57.41B 93M 2025-09
Rigel Pharmaceuticals USD 0 0 2024-09
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12